GS-4997, an Inhibitor of Apoptosis Signal-Regulating Kinase (ASK1), Alone or in Combination with Simtuzumab for the Treatment of Nonalcoholic Steatohepatitis (NASH): A Randomized, Phase 2 Trial
Publication
, Conference
Loomba, R; Lawitz, E; Mantry, PS; Jaya-kumar, S; Caldwell, SH; Arnold, H; Diehl, AM; Djedjos, CS; Jia, C; Myers, RP; Subramanian, M ...
Published in: HEPATOLOGY
December 1, 2016
Duke Scholars
Published In
HEPATOLOGY
EISSN
1527-3350
ISSN
0270-9139
Publication Date
December 1, 2016
Volume
64
Issue
6
Start / End Page
1119A / 1120A
Location
Boston, MA
Publisher
WILEY
Conference Name
67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD)
Related Subject Headings
- Gastroenterology & Hepatology
- 3204 Immunology
- 3202 Clinical sciences
- 1107 Immunology
- 1103 Clinical Sciences
- 1101 Medical Biochemistry and Metabolomics
Citation
APA
Chicago
ICMJE
MLA
NLM
Loomba, R., Lawitz, E., Mantry, P. S., Jaya-kumar, S., Caldwell, S. H., Arnold, H., … Charlton, M. R. (2016). GS-4997, an Inhibitor of Apoptosis Signal-Regulating Kinase (ASK1), Alone or in Combination with Simtuzumab for the Treatment of Nonalcoholic Steatohepatitis (NASH): A Randomized, Phase 2 Trial. In HEPATOLOGY (Vol. 64, pp. 1119A-1120A). Boston, MA: WILEY.
Loomba, Rohit, Eric Lawitz, Parvez S. Mantry, Saumya Jaya-kumar, Stephen H. Caldwell, Hays Arnold, Anna Mae Diehl, et al. “GS-4997, an Inhibitor of Apoptosis Signal-Regulating Kinase (ASK1), Alone or in Combination with Simtuzumab for the Treatment of Nonalcoholic Steatohepatitis (NASH): A Randomized, Phase 2 Trial.” In HEPATOLOGY, 64:1119A-1120A. WILEY, 2016.
Loomba R, Lawitz E, Mantry PS, Jaya-kumar S, Caldwell SH, Arnold H, et al. GS-4997, an Inhibitor of Apoptosis Signal-Regulating Kinase (ASK1), Alone or in Combination with Simtuzumab for the Treatment of Nonalcoholic Steatohepatitis (NASH): A Randomized, Phase 2 Trial. In: HEPATOLOGY. WILEY; 2016. p. 1119A-1120A.
Loomba, Rohit, et al. “GS-4997, an Inhibitor of Apoptosis Signal-Regulating Kinase (ASK1), Alone or in Combination with Simtuzumab for the Treatment of Nonalcoholic Steatohepatitis (NASH): A Randomized, Phase 2 Trial.” HEPATOLOGY, vol. 64, no. 6, WILEY, 2016, pp. 1119A-1120A.
Loomba R, Lawitz E, Mantry PS, Jaya-kumar S, Caldwell SH, Arnold H, Diehl AM, Djedjos CS, Jia C, Myers RP, Subramanian M, McHutchison JG, Goodman ZD, Afdhal NH, Charlton MR. GS-4997, an Inhibitor of Apoptosis Signal-Regulating Kinase (ASK1), Alone or in Combination with Simtuzumab for the Treatment of Nonalcoholic Steatohepatitis (NASH): A Randomized, Phase 2 Trial. HEPATOLOGY. WILEY; 2016. p. 1119A-1120A.
Published In
HEPATOLOGY
EISSN
1527-3350
ISSN
0270-9139
Publication Date
December 1, 2016
Volume
64
Issue
6
Start / End Page
1119A / 1120A
Location
Boston, MA
Publisher
WILEY
Conference Name
67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD)
Related Subject Headings
- Gastroenterology & Hepatology
- 3204 Immunology
- 3202 Clinical sciences
- 1107 Immunology
- 1103 Clinical Sciences
- 1101 Medical Biochemistry and Metabolomics